Leucemia linfatica cronica (Italian Wikipedia)

Analysis of information sources in references of the Wikipedia article "Leucemia linfatica cronica" in Italian language version.

refsWebsite

Global rank Italian rank

13doi.org

2^nd place

7^th place

9nih.gov

4^th place

9^th place

9oadoi.org

799^th place

22^nd place

2europepmc.org

8,929^th place

5,423^rd place

1archives-ouvertes.fr

1,031^st place

2,368^th place

1ascopubs.org

low place

1mjhid.org

low place

archives-ouvertes.fr

hal.archives-ouvertes.fr

(EN) Thomas Elter, Janne J. Vehreschild, John Gribben, Oliver A. Cornely, Andreas Engert, Michael Hallek, Management of infections in patients with chronic lymphocytic leukemia treated with alemtuzumab, in Annals of Hematology, vol. 88, n. 2, febbraio 2009, DOI:10.1007/s00277-008-0566-9, PMID 18682948.

ascopubs.org

(EN) M. J. Keating et al., Early Results of a Chemoimmunotherapy Regimen of Fludarabine, Cyclophosphamide, and Rituximab As Initial Therapy for Chronic Lymphocytic Leukemia, in Journal of Clinical Oncology, vol. 23, n. 18, 20 giugno 2005, pp. 4079–4088, DOI:10.1200/JCO.2005.12.051.

doi.org

dx.doi.org

(EN) Craig Sauter, Nicole Lamanna e Mark A. Weiss, Pentostatin in chronic lymphocytic leukemia, in Expert Opinion on Drug Metabolism & Toxicology, vol. 4, n. 9, 2008, pp. 1217-1222, DOI:10.1517/17425255.4.9.1217, PMID 18721115.
(EN) Cristina Florean, Michael Schnekenburger e Cindy Grandjenette, Epigenomics of leukemia: from mechanisms to therapeutic applications, in Epigenomics, vol. 3, n. 5, 1º ottobre 2011, pp. 581–609, DOI:10.2217/epi.11.73, PMID 22126248. URL consultato il 30 ottobre 2016.
(EN) Thomas Elter, Janne J. Vehreschild, John Gribben, Oliver A. Cornely, Andreas Engert, Michael Hallek, Management of infections in patients with chronic lymphocytic leukemia treated with alemtuzumab, in Annals of Hematology, vol. 88, n. 2, febbraio 2009, DOI:10.1007/s00277-008-0566-9, PMID 18682948.
(EN) M. Hallek, K. Fischer e G. Fingerle-Rowson, Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial (abstract), in The Lancet, vol. 376, n. 9747, 2 ottobre 2010, pp. 1164–1174, DOI:10.1016/S0140-6736(10)61381-5, PMID 20888994. URL consultato il 30 ottobre 2016.
(EN) M. Ghielmini, U. Vitolo e E. Kimby, ESMO Guidelines consensus conference on malignant lymphoma 2011 part 1: diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL) and chronic lymphocytic leukemia (CLL) (abstract), in Annals of Oncology, vol. 24, n. 3, 1º marzo 2013, pp. 561–576, DOI:10.1093/annonc/mds517, PMID 20888994. URL consultato il 30 ottobre 2016.
(EN) M. J. Keating et al., Early Results of a Chemoimmunotherapy Regimen of Fludarabine, Cyclophosphamide, and Rituximab As Initial Therapy for Chronic Lymphocytic Leukemia, in Journal of Clinical Oncology, vol. 23, n. 18, 20 giugno 2005, pp. 4079–4088, DOI:10.1200/JCO.2005.12.051.
(EN) Constantine S. Tam, Susan O'Brien e William Wierda, Long-term results of the fludarabine, cyclophosphamide, and rituximab regimen as initial therapy of chronic lymphocytic leukemia, in Blood, vol. 112, n. 4, 15 agosto 2008, pp. 975–980, DOI:10.1182/blood-2008-02-140582. URL consultato il 30 ottobre 2016.
(EN) Kenneth A. Foon, Michael Boyiadzis e Stephanie R. Land, Chemoimmunotherapy With Low-Dose Fludarabine and Cyclophosphamide and High Dose Rituximab in Previously Untreated Patients With Chronic Lymphocytic Leukemia, in Journal of Clinical Oncology, vol. 27, n. 4, 1º febbraio 2009, pp. 498–503, DOI:10.1200/JCO.2008.17.2619.
(EN) Kirsten Fischer, Paula Cramer e Raymonde Busch, Bendamustine in Combination With Rituximab for Previously Untreated Patients With Chronic Lymphocytic Leukemia: A Multicenter Phase II Trial of the German Chronic Lymphocytic Leukemia Study Group, in Journal of Clinical Oncology, vol. 30, n. 26, 10 settembre 2012, pp. 3209–3216, DOI:10.1200/JCO.2011.39.2688.
(EN) Luca Laurenti, Barbara Vannata e Idanna Innocenti, Chlorambucil plus Rituximab as Front-Line Therapy in Elderly/Unfit Patients Affected by B-Cell Chronic Lymphocytic Leukemia: Results of a Single-Centre Experience, in Mediterranean Journal of Hematology and Infectious Diseases, vol. 5, n. 1, 1º gennaio 2013, pp. e2013031, DOI:10.4084/MJHID.2013.031. URL consultato il 30 ottobre 2016.
(EN) Paola Bertazzoni, Cristina Rabascio e Federica Gigli, Rituximab and subcutaneous cladribine in chronic lymphocytic leukemia for newly diagnosed and relapsed patients (abstract), in Leukemia & Lymphoma, vol. 51, n. 8, 1º agosto 2010, pp. 1485–1493, DOI:10.3109/10428194.2010.495799. URL consultato il 30 ottobre 2016.
(EN) Peter Hillmen, Aleksander B. Skotnicki e Tadeusz Robak, Alemtuzumab compared with chlorambucil as first-line therapy for chronic lymphocytic leukemia, in Journal of Clinical Oncology, vol. 25, n. 35, 10 dicembre 2007, pp. 5616–5623, DOI:10.1200/JCO.2007.12.9098.
(EN) William G. Wierda, Swaminathan Padmanabhan e Geoffrey W. Chan, Ofatumumab is active in patients with fludarabine-refractory CLL irrespective of prior rituximab: results from the phase 2 international study, in Blood, vol. 118, n. 19, 10 novembre 2011, pp. 5126–5129, DOI:10.1182/blood-2011-04-348656.

europepmc.org

(ZH) Gu WJ , Xu W , Qian SX , Wu YJ , Hong M , Chen LJ , Wu HX , Lu H , Qiu HX , Li JY, [Treatment of chronic lymphocytic leukemia with regimen of fludarabine, cyclophosphamide and rituximab] ^{[collegamento interrotto]} (abstract), in Zhongguo Shi Yan Xue Ye Xue Za Zhi, agosto 2008, PMID 18718095.
(FR) Véronèse L, Tchirkov A, Gouas L, Périssel B, Goumy C, Vago P., [Prognosis of chronic lymphocytic leukemia: focus on recent biomarkers] (abstract), in Annales de Biologie Clinique, vol. 66, luglio 2008, pp. 371-377., PMID 18725337.

mjhid.org

(EN) Luca Laurenti, Barbara Vannata e Idanna Innocenti, Chlorambucil plus Rituximab as Front-Line Therapy in Elderly/Unfit Patients Affected by B-Cell Chronic Lymphocytic Leukemia: Results of a Single-Centre Experience, in Mediterranean Journal of Hematology and Infectious Diseases, vol. 5, n. 1, 1º gennaio 2013, pp. e2013031, DOI:10.4084/MJHID.2013.031. URL consultato il 30 ottobre 2016.

nih.gov

ncbi.nlm.nih.gov

(EN) Aki Z, Aksoy O, Sucak G, Kuruoglu R, Yagci M., Miller-Fisher syndrome associated with chronic lymphocytic leukemia, in Neurology India, vol. 56, aprile 2008, PMID 18688150.
(EN) Craig Sauter, Nicole Lamanna e Mark A. Weiss, Pentostatin in chronic lymphocytic leukemia, in Expert Opinion on Drug Metabolism & Toxicology, vol. 4, n. 9, 2008, pp. 1217-1222, DOI:10.1517/17425255.4.9.1217, PMID 18721115.
(EN) Cristina Florean, Michael Schnekenburger e Cindy Grandjenette, Epigenomics of leukemia: from mechanisms to therapeutic applications, in Epigenomics, vol. 3, n. 5, 1º ottobre 2011, pp. 581–609, DOI:10.2217/epi.11.73, PMID 22126248. URL consultato il 30 ottobre 2016.
(ZH) Gu WJ , Xu W , Qian SX , Wu YJ , Hong M , Chen LJ , Wu HX , Lu H , Qiu HX , Li JY, [Treatment of chronic lymphocytic leukemia with regimen of fludarabine, cyclophosphamide and rituximab] ^{[collegamento interrotto]} (abstract), in Zhongguo Shi Yan Xue Ye Xue Za Zhi, agosto 2008, PMID 18718095.
(EN) Thomas Elter, Janne J. Vehreschild, John Gribben, Oliver A. Cornely, Andreas Engert, Michael Hallek, Management of infections in patients with chronic lymphocytic leukemia treated with alemtuzumab, in Annals of Hematology, vol. 88, n. 2, febbraio 2009, DOI:10.1007/s00277-008-0566-9, PMID 18682948.
(EN) M. Hallek, K. Fischer e G. Fingerle-Rowson, Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial (abstract), in The Lancet, vol. 376, n. 9747, 2 ottobre 2010, pp. 1164–1174, DOI:10.1016/S0140-6736(10)61381-5, PMID 20888994. URL consultato il 30 ottobre 2016.
(EN) M. Ghielmini, U. Vitolo e E. Kimby, ESMO Guidelines consensus conference on malignant lymphoma 2011 part 1: diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL) and chronic lymphocytic leukemia (CLL) (abstract), in Annals of Oncology, vol. 24, n. 3, 1º marzo 2013, pp. 561–576, DOI:10.1093/annonc/mds517, PMID 20888994. URL consultato il 30 ottobre 2016.
(EN) Paola Bertazzoni, Cristina Rabascio e Federica Gigli, Rituximab and subcutaneous cladribine in chronic lymphocytic leukemia for newly diagnosed and relapsed patients (abstract), in Leukemia & Lymphoma, vol. 51, n. 8, 1º agosto 2010, pp. 1485–1493, DOI:10.3109/10428194.2010.495799. URL consultato il 30 ottobre 2016.
(FR) Véronèse L, Tchirkov A, Gouas L, Périssel B, Goumy C, Vago P., [Prognosis of chronic lymphocytic leukemia: focus on recent biomarkers] (abstract), in Annales de Biologie Clinique, vol. 66, luglio 2008, pp. 371-377., PMID 18725337.

oadoi.org

(EN) Craig Sauter, Nicole Lamanna e Mark A. Weiss, Pentostatin in chronic lymphocytic leukemia, in Expert Opinion on Drug Metabolism & Toxicology, vol. 4, n. 9, 2008, pp. 1217-1222, DOI:10.1517/17425255.4.9.1217, PMID 18721115.
(EN) Cristina Florean, Michael Schnekenburger e Cindy Grandjenette, Epigenomics of leukemia: from mechanisms to therapeutic applications, in Epigenomics, vol. 3, n. 5, 1º ottobre 2011, pp. 581–609, DOI:10.2217/epi.11.73, PMID 22126248. URL consultato il 30 ottobre 2016.
(EN) M. Hallek, K. Fischer e G. Fingerle-Rowson, Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial (abstract), in The Lancet, vol. 376, n. 9747, 2 ottobre 2010, pp. 1164–1174, DOI:10.1016/S0140-6736(10)61381-5, PMID 20888994. URL consultato il 30 ottobre 2016.
(EN) M. Ghielmini, U. Vitolo e E. Kimby, ESMO Guidelines consensus conference on malignant lymphoma 2011 part 1: diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL) and chronic lymphocytic leukemia (CLL) (abstract), in Annals of Oncology, vol. 24, n. 3, 1º marzo 2013, pp. 561–576, DOI:10.1093/annonc/mds517, PMID 20888994. URL consultato il 30 ottobre 2016.
(EN) Constantine S. Tam, Susan O'Brien e William Wierda, Long-term results of the fludarabine, cyclophosphamide, and rituximab regimen as initial therapy of chronic lymphocytic leukemia, in Blood, vol. 112, n. 4, 15 agosto 2008, pp. 975–980, DOI:10.1182/blood-2008-02-140582. URL consultato il 30 ottobre 2016.
(EN) Kenneth A. Foon, Michael Boyiadzis e Stephanie R. Land, Chemoimmunotherapy With Low-Dose Fludarabine and Cyclophosphamide and High Dose Rituximab in Previously Untreated Patients With Chronic Lymphocytic Leukemia, in Journal of Clinical Oncology, vol. 27, n. 4, 1º febbraio 2009, pp. 498–503, DOI:10.1200/JCO.2008.17.2619.
(EN) Kirsten Fischer, Paula Cramer e Raymonde Busch, Bendamustine in Combination With Rituximab for Previously Untreated Patients With Chronic Lymphocytic Leukemia: A Multicenter Phase II Trial of the German Chronic Lymphocytic Leukemia Study Group, in Journal of Clinical Oncology, vol. 30, n. 26, 10 settembre 2012, pp. 3209–3216, DOI:10.1200/JCO.2011.39.2688.
(EN) Peter Hillmen, Aleksander B. Skotnicki e Tadeusz Robak, Alemtuzumab compared with chlorambucil as first-line therapy for chronic lymphocytic leukemia, in Journal of Clinical Oncology, vol. 25, n. 35, 10 dicembre 2007, pp. 5616–5623, DOI:10.1200/JCO.2007.12.9098.
(EN) William G. Wierda, Swaminathan Padmanabhan e Geoffrey W. Chan, Ofatumumab is active in patients with fludarabine-refractory CLL irrespective of prior rituximab: results from the phase 2 international study, in Blood, vol. 118, n. 19, 10 novembre 2011, pp. 5126–5129, DOI:10.1182/blood-2011-04-348656.